ABT241220C117000
- 0.04
- -0.07-63.64%
Abbott Laboratories Newsroom
Unusual Options Activity: SLB, Z and Others Attract Market Bets, SLB V/OI Ratio Reaches 375.0
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $135
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Abbott Laboratories (ABT) Gets a Buy From Piper Sandler
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
This Is Why You Should Turn Defensive, Underweight Cyclicals – UBS
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Least Shorted S&P 500 Stocks in November
ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
Express News | Abbott : RBC Raises Target Price to $135 From $130
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Express News | Abbott's Freestyle Libre® 2 Now Reimbursed for Children and Adults Living With Diabetes in Alberta
Bernstein Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $133
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart
Should Weakness in Abbott Laboratories' (NYSE:ABT) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Another Week, Another Index Record | Lkive Stock
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $132 From $134, Maintains Buy Rating